myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced the expansion of their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers. Under a 2019 agreement, myTo
October 12, 2020
· 8 min read